Axcella Therapeutics up on promising data of NASH drug

Axcella Health

29/09/2022 11:56

** Shares of drug developer Axcella Therapeutics  AXLA.O 
sureg ~23% to $2.10 premarket
    ** Stock is among the biggest pct gainers across all U.S.
stocks trading before the bell
    ** Co reports positive mid-stage data on its experimental
drug to treat patients with a type of fatty liver disease called
Nonalcoholic Steatohepatitis (NASH)  urn:newsml:reuters.com:*:nBw7Y8q3ta
    ** Drug shows statistical significant improvement vs placebo
in liver stiffness and scarring at week 24 in trial - AXLA
    ** Patients administered the drug also demonstrated
statistically significant improvements in liver cell
inflammation and liver fat - AXLA
    ** Up to Wednesday's close, stock lost ~17% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))